ARID4B Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, engineered for the disruption of the ARID4B gene. This polyclonal pool provides a heterogeneous mixture of edited alleles, offering a robust loss-of-function model for studying ARID4B-dependent processes without clonal selection bias.
HT29 cells are a widely utilized human colorectal adenocarcinoma epithelial line initially established from a primary tumor in a 44-year-old female. They display characteristic epithelial morphology and serve as a standard model for colorectal cancer research, including oncogenic signaling, tumor pathophysiology, and therapeutic response evaluation. This background offers a clinically relevant epithelial context for examining ARID4B function in transcriptional regulation within cancer cells.
ARID4B encodes a core subunit of the SIN3A histone deacetylase (HDAC) complex, which mediates transcriptional repression through histone deacetylation at target gene promoters. Within this complex, ARID4B interacts with SIN3A, HDAC1, and HDAC2, forming a scaffold for chromatin remodeling and gene silencing. Its activity is modulated by upstream factors such as MYC and cell cycle signals, and it represses downstream effectors including MYC and CDKN1A. Disruption of ARID4B therefore derepresses these targets, perturbing cell cycle control and proliferation.
In the context of colorectal adenocarcinoma, ARID4B knockout HT29 polyclonal cells allow dissection of the epigenetic mechanisms sustaining malignant phenotypes. Loss of ARID4B-mediated repression alters histone acetylation dynamics genome-wide, potentially affecting pathways central to tumor cell survival, invasion, and chemoresistance. This model thus provides a powerful system for investigating how SIN3A/HDAC complex dysfunction contributes to colorectal cancer progression and for evaluating ARID4B-dependent gene networks.
Researchers can use these cells in diverse applications, including Western blotting for ARID4B and complex partners (SIN3A, HDAC1), RT-qPCR or RNA-seq transcriptomic profiling, ChIP-qPCR analysis of histone acetylation, and functional assays such as proliferation, colony formation, and apoptosis measurements. The model is particularly suited for HDAC inhibitor sensitivity studies and target validation in colorectal cancer. For more information, contact Ascent Research.
